Skip to main content

Table 2 GDC-0449 sensitizes H1299 cells to erlotinib/cisplatin

From: Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs

Erlotinib (A)10 μM

GDC (B)20 nM

Erlotinib + GDC [Expected (A+B)]

Erlotinib + GDC [Observed]

48.00 ± 1.8

12.81 ± 0.7

60.81 ± 1.9

68.60 ± 1.1

Cisplatin (C)9.9 μM

GDC (B)20 nM

Cisplatin + GDC [Expected (C+B)]

Cisplatin + GDC [Observed]

46.14 ± 3.1

12.81 ± 0.7

58.95 ± 2.8

71.93 ± 2.4

  1. The inhibition by erlotinib (A) and cisplatin (C) was calculated from the experiment shown in Figure 3C-D and all the values represent % Inhibition of H1299 cell proliferation under specified treatments. Erlotinib/cisplatin as well as GDC-0449 (GDC) (B) inhibited cell proliferation individually and the combination was significantly more effective.